ArticleInternational journal of cancer2012
Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells.
Article in International journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Visfatin (NAMPT) affects global gene expression in porcine anterior pituitary cells during the mid-luteal phase of the oestrous cycle.Journal of animal science and biotechnology · 2024Article
- Investigation of the inhibitory behavior of XFE and mitoxantrone molecules in interaction with AKT1 protein: a molecular dynamics simulation study.Journal of molecular modeling · 2023Article
- Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.Scientific reports · 2022Article
- Genetic Deficiency of MicroRNA-15a/16-1 Confers Resistance to Neuropathological Damage and Cognitive Dysfunction in Experimental Vascular Cognitive Impairment and Dementia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- LINC01207 promotes prostate cancer progression by sponging miR-1182 to upregulate AKT3.Oncology letters · 2022Article
- AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization.Cancers · 2022Article
- Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies.Frontiers in pharmacology · 2022Review
- Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay.Cancers · 2021Review
- Article
- A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1.Molecular cancer · 2019Article
- Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.Cancer research and treatment · 2019Article
- Genome-wide DNA methylation profiles in Tibetan and Yorkshire pigs under high-altitude hypoxia.Journal of animal science and biotechnology · 2019Article
- Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues.Genes & cancer · 2017Article
- MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.Oncotarget · 2016Article
- Molecular biology of gynecological cancer.Oncology letters · 2016Article
- Cancer Markers Selection Using Network-Based Cox Regression: A Methodological and Computational Practice.Frontiers in physiology · 2016Article
- Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF.Journal of Cancer · 2014Article
- miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development.Cell death & disease · 2013Article
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Cancer metastasis reviews · 2012Review
- Arterial insulin resistance in Yucatan micropigs with diet-induced obesity and metabolic syndrome.Journal of diabetes and its complicationsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The PI3 kinase/Akt pathway is commonly deregulated in human cancers, functioning in such processes as proliferation, glucose metabolism, survival and motility. We have previously described a novel function for one of the Akt isoforms (Akt3) in primary endothelial cells: the control of VEGF-induced mitochondrial biogenesis. We sought to determine if Akt3 played a similar role in carcinoma cells. Because the PI3 kinase/Akt pathway has been strongly implicated as a key regulator in ovarian carcinoma, we tested the role of Akt3 in this tumor type. Silencing of Akt3 by shRNA did not cause an overt reduction in mitochondrial gene expression in a series of PTEN positive ovarian cancer cells. Rather, we find that blockade of Akt3, results in smaller, less vascularized tumors in a xenograft mouse model that is correlated with a reduction in VEGF expression. We find that blockade of Akt3, but not Akt1, results in a reduction in VEGF secretion and retention of VEGF protein in the endoplasmic reticulum (ER). The reduction in secretion under conditions of Akt3 blockade is, at least in part, due to the down regulation of the resident golgi protein and reported tumor cell marker, RCAS1. Conversely, over-expression of Akt3 results in an increase in RCAS1 expression and in VEGF secretion. Silencing of RCAS1 using siRNA inhibits VEGF secretion. These findings suggest an important role for Akt3 in the regulation of RCAS1 and VEGF secretion in ovarian cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.